Stock Analysis, Dividends, Split History

MRNS / Marinus Pharmaceuticals, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price8.78
Volume2,068,300.00
Market Cap ($M)326.63
Enterprise Value ($M)305.16
Book Value ($M)45.02
Book Value / Share1.11
Price / Book7.26
NCAV ($M)43.74
NCAV / Share1.08
Price / NCAV7.47
Share Statistics
Common Shares Outstanding 40,520,705
Preferred Stock Shares Outstanding 0
Common Stock Shares Outstanding 40,520,705
Scoring Models
Piotroski F-Score1.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-0.33
Return on Assets (ROA)-0.60
Return on Equity (ROE)-0.88
Balance Sheet (mrq) ($M)
Assets48.69
Liabilities3.67
Quick Ration/a
Current Ratio13.32
Income Statement (mra) ($M)
Operating Income-19.04
Net Income-18.90
Earnings Per Share Basic And Diluted-0.80
Cash Flow Statement (mra) ($M)
Cash From Operations-18.82
Cash from Investing-21.42
Cash from Financing-21.42
Identifiers and Descriptors
CUSIP56854Q101
Central Index Key (CIK)1267813

Split History

Stock splits are used by Marinus Pharmaceuticals, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon
MRNS: Marinus Pharmaceuticals Analysis and Research Report

2018-04-27 - Asif

Overview Marinus Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing and commercializing innovative therapeutics to treat epilepsy and neuropsychiatric disorders. The company's clinical stage product candidate, ganaxolone, is a positive allosteric modulator of GABAA being developed in three different dose forms: intravenous (IV), capsule and liquid. The multiple dose forms are intended to maximize the therapeutic range of ganaxolone for adult and pediatric patient populations, in acute and chronic care, and both in-patient and self-administered settings. Ganaxolone exhibits anti-seizure, anti-anxiety and anti-depressive actions via its effects on synaptic and extrasynaptic GABAA receptors. The company's Pipeline Marinus Pharmaceuticals is developing ganaxolone to treat children suffering from rare epilepsies and both adults and children suffering from other neuropsychiatric conditions where there is a mechanistic rationale for ganaxolo...

Related News Stories

10 Killer Stocks to Buy That No One Knows About  

2018-08-06 investorplace
We have all heard about the big stocks a million times. That’s not to say they are bad investing prospects. Not at all. Amazon (NASDAQ:AMZN), for example, is an expensive stock with robust growth potential. (62-10)

GW Pharmaceuticals: Value Beyond Epidiolex?

2018-06-04 seekingalpha
GW has Sativex ready for a Phase 3 study in an indication that already has approval in several countries outside of the US. (120-0)

How To Use Probabilities In Investing: Open Sources

2018-05-11 seekingalpha
(In whose favor are the odds of this particular game, hmm? Image by Own work, CC BY-SA 3.0, source) (83-0)

BRIEF-Marinus Pharmaceuticals Reports Quarterly Loss Per Share $0.15

2018-05-02 reuters
* MARINUS PHARMACEUTICALS INC - AT MARCH 31, 2018, HAD CASH, CASH EQUIVALENTS AND INVESTMENTS OF $52.0 MILLION, COMPARED TO $58.4 MILLION AT DECEMBER 31, 2017 (71-0)

Ovid Therapeutics: Beaten Down IPO With Upcoming 2018 Catalysts

2018-05-01 seekingalpha
Data from the phase 2 STARS trial for OV101 in Angelman’s syndrome is expected in Q3, 2018. (204-0)

CUSIP: 56854Q101